Podcasts about Biotechnology

What does it look like to take a neuroscience degree far beyond the lab? In this episode, we explore a career path that crosses scientific research, government regulation, and biotech entrepreneurship with Dr. Amanda Wiggins, CEO of The cGP Lab. Amanda began her career investigating neurodegeneration and cortical spreading depression. Over time, her passion for real-world impact led her into public policy—where she helped shape New Zealand's Human Tissue Act and advised on regulations for stem cell research and genetic technologies. Today, she leads a company advancing neuroprotective health supplements based on cyclic Glycine-Proline (cGP), a molecule with growing potential in aging and cognitive health. We talk about: How to navigate transitions between academia, government, and business The challenges of working across disciplines—and how to build confidence in new spaces Lessons learned from leading regulatory change and scaling innovation Amanda's work at The cGP Lab and the science behind cGP's potential in brain health Advice for scientists who want to move into leadership, entrepreneurship, or public engagement This conversation is for anyone considering a non-linear career in neuroscience or wondering how to apply scientific training in new and meaningful ways. Chapters: 00:00:02 - Bridging Neuroscience and Biotech Innovation 00:04:06 - FDA Approval of Trofinetide for Rett Syndrome 00:07:27 - My Journey in Science and Identity 00:09:22 - Pursuing a PhD in Melbourne 00:11:55 - Choosing a PhD Topic 00:17:26 - Challenges and Motivation in PhD Journey 00:20:54 - Transition from Academia to Regulatory Work 00:22:52 - Transitioning from Academia to Policy 00:25:51 - Advising on the Human Tissue Act 00:29:18 - Advocating Biotechnology in New Zealand 00:33:51 - Regulations and Challenges in Biotechnology 00:37:49 - Newborn Blood Screening and Research Ethics 00:41:22 - Transitioning from Science to Biotech 00:46:04 - Challenges of Startup Success 00:48:34 - Journey to Neuroactive Innovation 00:55:23 - Mentorship and Startup Advice 00:58:49 - Dementia Prevention and Early Detection 01:02:03 - Exploring Alzheimer's Research Frontiers 01:06:45 - Advancing Your Neurocareer About the Podcast Guest:

Welcome to The Plaidchat- an extension of The Plaidcast where we expand upon conversations in our sport and discuss the most recent issue of The Plaid Horse Magazine. Piper speaks with TPH Small business winner, Caitlin Looney of Extend Equine Massage. Listen in and share with friends!Host: Piper Klemm, publisher of The Plaid HorseGuest: Caitlin Looney is a certified equine bodyworker and owns Extend Equine Massage, which services the Massachusetts and New Hampshire areas offering equine massage, kinesiology taping, red light therapy and more! Holding her Masters in Biotechnology, Caitlin brings a unique scientific understanding of the horse's muscular system to her practice to provide reproducible and significant results. Riding at such diverse levels herself ranging from 4H to the breed level, Caitlin appreciates all aspects of competition and enjoys supporting a wide array of clients from the retired pony to the high performing equine athlete.Read the Latest Issue of The Plaid Horse MagazineSubscribe To: The Plaid Horse MagazineTitle Sponsor: Taylor, Harris Insurance ServicesSponsors: Taylor, Harris Insurance Services, BoneKare and Great American Insurance Group Join us at an upcoming Plaidcast in Person event!

The podcast edition of Charlottesville Community Engagement marks the end of the workweek for the devoted staff at Town Crier Productions and the beginning of the next one. The mission is to write as much as possible and to always strive to capture more. The podcast edition reaches about a tenth of the audience for the written version. From a production standpoint, they're the same thing - stories about the community that may help you understand some of the shifting dynamics. I'm Sean Tubbs, and I'm glad to be able to bring this information to you.On this edition:* Inaugural director of Manning Institute of Biotechnology shares vision with UVA Board (learn more)* UVA surpasses $6 billion in major fundraising campaign (learn more)* Charlottesville Planning Commission briefed on forthcoming updates to zoning code (learn more)* UVA provides update on construction projects to Charlottesville Planning Commission (learn more)* City parks and recreation put garden plot term limits on hold (learn more)* Albemarle County Supervisors get briefings on the cost of county services as well as economic development (stories come out on Monday)Charlottesville Community Engagement is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Soul-searching SaturdayThere are no shout-outs in the print edition but I'll take this Saturday afternoon to write up the current state of that form of public announcements. I've strived to be transparent with how my company makes revenue.Prior to launching this newsletter on July 13, 2020, I launched a Patreon account for people who wanted to provide seed money for the overall venture. I did not know how I would distribute the work. At the time, my work consisted of a podcast called the Charlottesville Quarantine Report.That went out through Simplecast, and I still pay $15 a month to host the work until I can figure out a more permanent place for it to live. I think it is a valuable archive of a time in history. If you want to hear one, go back and listen to the June 8, 2020 edition which gave an update on what local government was doing.Producing that program made me want to move forward with this newsletter, which was a podcast for almost all of the first 700 editions. These were very short in nature at first but expanded over time as I got used to doing the work.If you look at the print version of the July 13, 2020 edition, there is no shout-out. There are also no pictures. No headlines. It's literally a radio script. If you take a listen, you'll hear a shout-out to Rapture. I put that in as a placeholder as I spent some time in public radio and wanted to do something. At the time, the place had reopened under COVID rules and it was where I spent time away from home.In the July 15, 2020 edition, I noted that Mead Oriental Rugs was supporting the show in both the print and the written versions. I'm friends with the owner. There was no money exchanged.In the fourth version, College Inn was a shout-out. One of the owners let me do this and I don't remember if we had any sort of an arrangement or not. They're now gone.This continued for those first few weeks with me adding in others here and there, even promoting the Charlottesville Podcasting Network. That's the site I created in 2005 as an experiment in audio distribution.By the 14th edition of the newsletter, I began to implement something from the Patreon world. For most of the time of the site, if you paid $25 a month through Patreon, you'd get a certain number of “shout-outs” in the newsletter. I began to track these, as there were many people willing to support the work.And so on. Now we're up to 879 editions of the regular newsletter, and over 315 editions of the Week Ahead newsletter. All produced by one person. However, the business has grown incrementally, and there is now much in the shout-out system that needs to be fixed.I'm hoping to do that over the course of the year. I'm no longer taking any new requests under the old system but I have two paid advertisers who are going to work with me as I begin to put the new system in place. This will be a mixture of message here in Substack, banner ads on Information Charlottesville, as well as mentions in the podcast.The shout-out will continue and the new policy will contain some way of getting public service announcements. There are thousands of you reading this newsletter and I suspect that number will grow as more people learn.Now I need to get going because the next set of stories beckon. Thank you for reading to this point if you did. If you didn't read to this point, please know I'm waving at you and saying hello anyway.Thanks for reading Charlottesville Community Engagement ! This post is public so feel free to share it. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit communityengagement.substack.com/subscribe

In celebration of Pride Month, we're sharing two stories about coming out with the help of science. Part 1: After years of struggling with their gender identity, Parker Sublette finds inspiration in marine life. Part 2: Bullied as a kid for the sound of his voice, Garret Glinka begins to reclaim his confidence thanks to biology class. Parker Sublette is a comedian and speculative fiction writer living in Brooklyn, New York. She can usually be found scrambling around the city looking for any stage that will have her, or at home with her roommates and their two cats. Parker also sometimes hosts an open-mic in Bushwick, you can find her @parks_jokez on instagram. Garret Glinka: I wear two hats: one as a businessman with half a Master's in Business, and the other as a scientist, with another half in Biotechnology and Genomics, complemented by a Bachelor's in Biological Sciences. My background allows me to bridge the administrative and scientific worlds. Over the past six years, I've honed my expertise as a laboratory professional in both corporate and academic settings, helping operate and set up five laboratories domestically/internationally. I've been a technician, team leader, supervisor, and lab manager. As a member of the queer community, I bring kindness, authenticity, vulnerability, and positive influence to my leadership style. Now at Columbia University's Neuroscience Institute, I manage two labs, lead the Gender and Inclusion Mentoring Program, and coordinate the Lab Liaison Group, ensuring communication across the institute's departments and other lab managers. When I'm not dissecting Drosophila in New York City, or out to eat with Jersey City friends, I retreat to my family's farm in central New Jersey. There you'll find me tending to our goats and chickens, inspecting the crops, or racing dirt bikes with my three-year-old nephew, Jay. My life is a dynamic blend of science, leadership, community, and family, each enriching the other in unexpected ways. Learn more about your ad choices. Visit megaphone.fm/adchoices

Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of that figure. Not surprising when you think that healthcare focused biotech companies are battling to solve some of our biggest health concerns; turning an ageing society into a longevity society by supporting longer and healthier lives. In this episode of The Next Five, Paul Little, CEO of Vesper Bio discusses frontotemporal dementia and the impact of it on human health and society, the biotech solutions being sort to combat the disease as well as what he describes as a Malthusian crisis around biotech funding. Dr Ann Beliën, Founder and CEO of Rejuvenate Biomed addresses the problems of Sarcopenia as well as the biotech solutions for it and how Biotech companies use creative ways to secure funding. Gianmario Verona, President of Human Technopole, highlights the importance of industry collaboration and how innovation centres can help propel the biotech sector forward. Sources: FT Resources, WHO, JP Morgan, Alzheimersresearchuk, IQVIA This content is paid for by Yes Milano and is produced in partnership with the Financial Times' Commercial Department. Hosted on Acast. See acast.com/privacy for more information.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, AppleTV or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Nicole: Willingness to take bold leaps and embrace the unknown.Imagine a world where cancer is as treatable as the flu. That's the vision Nicole Paulk, the founder and CEO of Siren Biotechnology, is working tirelessly to bring to life. Driven by groundbreaking science, Nicole's company is on the brink of launching clinical trials for a revolutionary cancer treatment.Nicole's work leverages engineered viruses—those that don't make you sick—to deliver genetic medicines directly to cancer cells. These “good viruses” act as a delivery system for anti-tumor drugs, targeting difficult-to-treat cancers like recurrent high-grade gliomas, a fatal brain cancer. “We started to see data that looked really promising in this space,” Nicole explained, adding, “We felt a moral obligation to go after this cancer where there's just this huge unmet need.”Siren Biotechnology's approach is designed to have broad applications. Unlike treatments that target specific genetic mutations, their method has the potential to work on various tumor types. Nicole describes it as using viruses like a “little FedEx delivery truck” that can be engineered to deliver medicine precisely where it's needed in the body.This innovation didn't happen overnight. Nicole, a former professor of virology at UCSF, took the bold step of leaving academia to launch Siren Biotechnology. “I decided to resign from my faculty position and go be the founder and CEO just because I was so excited about the data and what we had so far,” she shared.In addition to traditional venture capital funding, Siren Biotechnology is inviting the public to invest through a regulated investment crowdfunding campaign. This unique opportunity allows patients, families, and supporters touched by cancer to be part of their journey. “We wanted to bring patients and their families onto our cap table,” Nicole said. “It's a way to involve them in the conversation much earlier.”Siren Biotechnology's work could redefine cancer care and inspire a new model for patient-centered innovation. With clinical trials just months away, the future looks brighter for those battling cancer—and for all of us who dream of a world where cancer is no longer a death sentence.tl;dr:Nicole Paulk's Siren Biotechnology transforms viruses into targeted cancer therapies with universal potential.The company focuses on recurrent high-grade gliomas, a fatal brain cancer with no standard treatment.Nicole left academia to lead Siren, leveraging her groundbreaking virology research to launch the company.Siren's unique crowdfunding campaign lets patients and families invest in the fight against cancer.Nicole's superpower, fearless innovation, drives her bold mission to revolutionize cancer care.How to Develop Fearless Innovation As a SuperpowerNicole's superpower is her willingness to take bold leaps and embrace the unknown. After spending nearly two decades building her academic career, Nicole left her position as a virology professor at UCSF to start Siren Biotechnology. She explained, “I feel like my superpower is just kind of being willing to jump off the cliff without a parachute and be like, we're going to figure it out. We're going to make it work.”Nicole exemplified fearless innovation when her research led to a groundbreaking discovery about the biology of a virus, one that required rewriting existing textbooks. Initially met with skepticism, her work was later validated and became a foundation for Siren Biotechnology's cancer treatment. This pivotal moment highlights Nicole's courage to challenge conventional knowledge and pursue transformative ideas.Tips for Developing This Superpower:Be willing to question conventional wisdom and explore new paths.Take calculated risks, even if it means stepping away from a well-defined career path.Embrace discomfort and uncertainty as a necessary part of innovation.Engage others by communicating your vision in relatable and accessible ways.By following Nicole's example and advice, you can make fearless innovation a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileNicole Paulk (she/her):CEO, Founder, President, Siren BiotechnologyAbout Siren Biotechnology: We are combining two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy – into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity.This is the first AAV gene therapy drug product that can be made once and used in numerous indications – a huge leap forward for the field. This drastically reduces clinical development times, manufacturing timelines, and capital needs for each clinical trial. Most importantly, ‘universal' means countless solid tumor cancer patients – regardless of tumor type or mutations – may benefit from this breakthrough approach.Website: sirenbiotechnology.comX/Twitter Handle: @SirenBioCompany Facebook Page: facebook.com/SirenBiotechnologyOther URL: wefunder.com/siren.biotechnologyBiographical Information: Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases.Before founding Siren, Nicole held various leadership positions in academia and industry and most notably was an Assistant Adj Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren. Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU, and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF. Nicole is a pioneer in the development of next-generation AAV platforms for gene repair, gene transfer and gene editing, directed evolution for novel engineered capsid evolution, and comparative multi-omic approaches to interrogate translational AAV biology.Nicole is a renowned expert in gene therapy and has consulted extensively for big pharma, written draft CMC guidance for the FDA, and sits on the Scientific Advisory Boards for Sarepta, Astellas, Metagenomi, Dyno Therapeutics, CEVEC, GRO Biosciences, Excision BioTherapeutics, WhiteLab Genomics, Johns Hopkins Gene Therapy Initiative, the Gene Therapy for Rare Disorders Searchlight Program, and several stealth startups. She has been quoted in The Wall Street Journal, The Economist, The Boston Globe, Endpoints, STAT, Phacilitate, GEN, BioPharma Dive, Evaluate Vantage, SF Business Times, WIRED, Drug Discovery World, MIT Tech Review, C&EN, and more. She sits on the Scientific Editorial Boards of the journals Gene Therapy, Human Gene Therapy, and Biopharma International Gene Therapy. She is the Chair of the American Society of Gene and Cell Therapy (ASGCT) Translational Science Committee, and a member of the ASGCT Cancer Cell and Gene Therapy Committee and the Biocom California Cell and Gene Therapy Committee. She has invented numerous AAV gene therapy technologies that have been shared or licensed to dozens of gene therapy companies and nonprofit groups working in rare diseases.Outside of work, you can find Nicole adventure traveling (think whitewater rafting meets backcountry trekking), snowboarding, planning elaborate Halloween parties complete with animatronics and ghoulish menus, tending her vegetable garden, and obsessing over the latest wearable gadgets. If you're trying to track her down at a conference and can't find her, it's because she snuck off to an oyster bar.X/Twitter Handle: @Nicole_PaulkLinkedin: linkedin.com/in/nicolepaulkInstagram Handle: @sirenbioSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, Kingscrowd and Crowdfunding Made Simple. Learn more about advertising with us here.Max-Impact MembersThe following Max-Impact Members provide valuable financial support:Carol Fineagan, Independent Consultant | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Ralf Mandt, Next Pitch | Scott Thorpe, Philanthropist | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on June 17, 2025, at 1:00 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, June 18, 2025, at 12:00 PM Eastern. Jason Fishman, Co-Founder and CEO of Digital Niche Agency (DNA), will lead a session on "How to Spin $1 of Advertising into $10!" He'll reveal proven strategies and marketing insights drawn from years of experience helping successful crowdfunding campaigns. Whether you're a founder planning a raise or a supporter of innovative startups, you'll gain actionable tips to boost visibility, drive engagement, and hit your funding goals. Don't miss it!Join us on June 25, 2025, at 8:00 PM Eastern for the Superpowers for Good Live Pitch—streaming on e360tv, where purpose-driven founders take the virtual stage to present their active Regulation Crowdfunding campaigns to a national audience of investors and changemakers. Selected startups are chosen for their commitment to community, alignment with NC3's Community Capital Principles, and their drive to create real-world impact. Thanks to sponsors DNA and DealMaker, this event is free to watch and amplifies the voices of underrepresented and mission-aligned entrepreneurs. Don't miss this inspiring evening where capital meets purpose—tune in to discover and support the next wave of impact-driven innovation.SuperCrowd25, August 21st and 22nd: This two-day virtual event is an annual tradition but with big upgrades for 2025! We'll be streaming live across the web and on TV via e360tv. Soon, we'll open a process for nominating speakers. Check back!Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Devin Thorpe is featured in a free virtual masterclass series hosted by Irina Portnova titled Break Free, Elevate Your Money Mindset & Call In Overflow, focused on transforming your relationship with money through personal stories and practical insights. June 8-21, 2025.Join Dorian Dickinson, founder & CEO of FundingHope, for Startup.com's monthly crowdfunding workshop, where he'll dive into strategies for successfully raising capital through investment crowdfunding. June 24 at noon Eastern. Regulated Investment Crowdfunding Summit 2025, Crowdfunding Professional Association, Washington DC, October 21-22, 2025.Call for community action:Please show your support for a tax credit for investments made via Regulation Crowdfunding, benefiting both the investors and the small businesses that receive the investments. Learn more here.If you would like to submit an event for us to share with the 9,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Phytoremediation. A fun word to say, but what does it mean? Turns out it's quite simple: using the superpower many plants naturally have to heal our wonderful Earth from terrible soil contaminants. Allan pulls us off the dark abyss edge that is our current world to deliver a wonderful tale of plants. Primary Sources: Gerhardt KE, Gerwing PD, Greenberg BM. Opinion: Taking phytoremediation from proven technology to accepted practice. Plant Sci. 2017 Mar;256:170-185. Epub 2016 Dec 5. PMID: 28167031. Lee, Jae. (2013). An overview of phytoremediation as a potentially promising technology for environmental pollution control. Biotechnology and Bioprocess Engineering. 18. +++ More of Our Work +++ Website Facebook TikTok Twitch Bluesky +++ Contact Us +++ Text/Call: (316)-512-8933 info@grasslandgroupies.org +++ Support Us +++ Bonfire Merch Store CashApp: $GrasslandGroupies Or... donate directly to our org.

In this episode, we sit down with Dr. Mark Esser, the inaugural Chief Scientific Officer of UVA's new Paul and Diane Manning Institute of Biotechnology. Dr. Esser, a renowned expert in immunology and vaccine development, shares his journey from AstraZeneca to leading this ambitious institute. With a vision to revolutionize healthcare and accelerate the development of life-saving treatments, Mark discusses fostering innovation, attracting biotech companies to Virginia, and the future of personalized medicine.

In this episode of Speaking of Mol Bio, Dr. Cath Moore of the Australian Genome Research Facility (AGRF) discusses how molecular biology technologies are helping to shape Australia's scientific landscape—from clinical genomics and conservation to bioremediation and agriculture. With over 20 years of experience in both academia and industry, Dr. Moore reflects on the remarkable evolution of genomic tools, from Sanger sequencing to high-resolution spatial multiomics.She unpacks AGRF's mission to democratize access to emerging technologies and highlights its role as an early adopter of platforms that help scientists translate academic research into real-world impact. Topics include non-mass spec proteomics, mine site rehabilitation through soil microbiome analysis, and the role of systems biology in modern science.Dr. Moore also discusses the importance of community education and literacy around genomics, emphasizing how public understanding is key to the safe adoption of emerging technologies like synthetic biology. Finally, she shares career insights and advice for aspiring scientists: stay curious, stay broad, and don't be afraid to pivot when your work no longer brings joy. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of the Fitness + Technology Podcast, Bryan O'Rourke shares his keynote, “The Key Trends Creating Opportunities and Challenges for the Global Fitness Industry in the Next 5 Years” live from Beyond Activ in Singapore. Bryan shares the spotlight for what's next for fitness across the globe — from emerging technologies and programming innovations to finance, business models, and the forces reshaping how to serve members and scale impact. Whether you lead a gym, studio, supplier brand, or digital platform, this talk is designed to challenge your thinking and equip you for what's ahead. To view the slideshow, go to: https://www.slideshare.net/slideshow/future-of-fitness-2025-keynote-bryan-orourke-beyond-activ-singapore-2025/280332550 One Powerful Quote: 7:41: “In a world deluged by irrelevant information, clarity is power.” 4-10 Bullet Points (w/ timestamps) - Highlighting key topics discussed: 3:09: Bryan opens his keynote with “What if?” and the convergence of macro/micro trends.  7:47: Bryan talks about opportunities and challenges in the next 5 years.  11:31: Bryan articulates on business models as the mainstay configurations for fitness delivery.  15:40: Bryan speaks on biotechnologies and the new social constructs today.  17:40: Bryan defines leadership vision and the processes to execute on it.  19:09: Bryan recaps his presentation.  Bullet List of Resources: https://beyondactiv.com/ Guest Contact Information: https://www.bryankorourke.com/ https://www.linkedin.com/in/bryankorourke/ http://www.fittechcouncil.org/ https://www.youtube.com/user/bko61163

Explore the science behind genetically engineered probiotics with Zack Abbott, PhD of ZBiotics. We talk about hacking gut bacteria to reduce hangovers and turn sugar into fiber—plus why bacterial diversity is key to better health. Lindsey Parsons, your host, helps clients solve gut issues and reverse autoimmune disease naturally. Take her quiz to see which stool or functional medicine test will help you find out what's wrong. She's a Certified Health Coach at High Desert Health in Tucson, Arizona. She coaches clients locally and nationwide. You can also follow Lindsey on Facebook, Tiktok, X, Instagram or Pinterest or reach her via email at lindsey@highdeserthealthcoaching.com to set up your free 30-minute Gut Healing Breakthrough Session. Show Notes

When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in biotechnology, corporate VC money can be an attractive way for biotechs to raise funds privately while benefiting from the support and expertise of corporate supporters.This week I talked with Paolo Di Giorgio and Regina Hodits of Angelini Ventures, the corporate VC arm of Angelini Industries, itself the parent company of Angelini Pharma. Paolo and Regina lay out their perspective on the current fundraising landscape, identify the trends and opportunities for innovative biotechs in Europe, and walk me though the biggest threats to the biotech investment market they see on the near horizon.01:15               Introducing Paolo Di Giorgio04:00               Introducing Regine Hodits05:31               The mission of Angelini Ventures09:55               Focus areas and investments in early stage science14:30               The state of venture capital investment in biotech in 202517:48               Why biotechs should favor corporate venture capital20:43               Why networking and expertise matter in fundraising26:05               The therapeutic areas and modalities that are hot right now29:19               Geographic focus for corporate venture capital33:28               Threats on the horizon36:36               What keeps a corporate VC investor up at night?40:13               Keep in touch with Angelini VenturesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

In 2019, a study from Denmark by Hviid, et al, purported to demonstrate that there was no link between the MMR vaccine and autism, even among genetically susceptible populations.The study was strongly critiqued at the time, and now, journalist Jeremy R. Hammond, along with Dr. Brian Hooker and Dr. Jeet Varia, has published a paper that addresses the serious flaws in Hviid et al, in the Journal of Biotechnology and Biomedicine. I talk with Jeremy about Hviid et al, and about his own paper, and about the state of research into the connection between vaccines and autism more broadly.Links:Hviid et al. 2019Jeremy's paperThis article summarizes key points from Jeremy's paper:I discussed medical licensing with Jeremy here.Jeremy exposes the WaPo's Lena Sun here....and the AAP's “vaccines do not cause autism” claim, here.Jeremy's book, "The War on Informed Consent" is one of the most concise and informative works on the suppression of science and discussion regarding vaccines.https://www.jeremyrhammond.com/product/the-war-on-informed-consent/You can find Jeremy here, and here. 

Our guest this week, Lara Campana is SVP of Research & Translational Science and a co-founder of Resolution Therapeutics, a company developing regenerative macrophage therapies for inflammatory and fibrotic diseases. In this episode of Careers in Discovery, Lara shares her journey from medical Biotechnology student in Milan to Biotech executive in the UK, and why she's been fascinated by macrophages ever since a single line in a university lecture hinted at their regenerative potential. We talk about the origins of Resolution, how the company grew from a trio of postdocs in a university lab to a clinical-stage Biotech, and the challenges of leading teams, building culture, and letting go as a founder. Lara also reflects on the mindset shift from academic research to pragmatic, patient-focused drug development - and the lessons she's learned along the way about influence, resilience, and finding space to think.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Regeneron's shares have dropped due to the failure of their dupixent follow-up drug, while Sanofi has acquired Blueprint for $9.5 billion to expand their rare disease portfolio. Bristol Myers Squibb is collaborating with Biontech on a bispecific antibody for solid tumors, and Amgen's imdelltra has shown a 40% increase in survival for small cell lung cancer at ASCO. Moderna has received FDA approval for their next-gen COVID-19 vaccine, and AstraZeneca is partnering with AI companies to stop cancer at all stages. Keros has cut 45% of its workforce along with a pulmonary hypertension drug, and Jazz has presented new cancer data at ASCO. FDA actions are pending for companies like Merck, Gilead, and Regeneron/Sanofi.The implications of the overturning of the FDA's lab-developed tests rule in a post-Chevron legal landscape are discussed, where power has shifted from federal agencies to the courts. Upcoming FDA decisions, including Gilead's HIV prophylaxis lenacapavir, are highlighted, along with new FDA guidelines on nitrosamine testing for the pharmaceutical industry. Jazz Pharmaceuticals is in the "goldilocks zone" with new cancer data at ASCO25, showcasing results from acquisitions made over the past five years. Zeiss introduces an AI-powered spatial biology solution for research labs. Other news includes updates from ASCO25, cell and gene therapy developments, and upcoming events in the biopharma industry.

Can science turn any blood into a universal donor type? Join us in this episode as we explore groundbreaking healthcare innovations with Maher Abou Hachem, a distinguished Professor in the Department of Biotechnology and Biomedicine at the Technical University of Denmark. Maher's expertise spans recombinant protein production, purification, biomolecular interactions, stability, and enzymology. From gut microbiome studies to pioneering blood type conversion, his cutting-edge research is reshaping the future of healthcare. Are you ready to find out what makes Maher's work so unique? Hit play to find out! Dive in now to discover: What the major blood types are, and how they are used in transfusion and transplant applications. What happens if you give the wrong blood type to a patient. How researchers can change one blood type to another. The significance of red blood cells in the human body. You can learn more about Maher and his investigations here! Episode also available on Apple Podcasts: http://apple.co/30PvU9

IN today's episode podcast, host Kerry Lonergan sits down with up with US animal genetics expert and award winning ag communicator Professor Alison Van Eenaammen. Prof Van Eenennaam is a distinguished Professor of Cooperative Extension in the field of Animal Genomics and Biotechnology in the Department of Animal Science at  the University of California, Davis where she has been on faculty for over 20 years. She spoke at the recent World Angus Congress in Brisbane on the opportunities and challenges for DNA and biotechnology in the beef industry.         The Weekly Grill is brought to listeners by Rhinogard and Bovi-Shield MH-One, the One Shot, One Spray, One Time BRD Vaccines by Zoetis.    

Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McKenzie's Roel Meers, understanding where the market is moving is where he eats.I spoke to Roel this week to unpack just where biotech funding stands in Q2 2025, to get a feel for the sorts of M&As, IPOs, and licensing deals we should be looking for in the second half of the year. We also talk about some alternative financing options for innovators and early-stage firms.01:09                      Introducing Roel Meers02:18                     Corporate finance and the life sciences04:53                      Brussels, Europe, and beyond: Baker McKenzie's global footprint06:21                      Navigating life science regulations and regulators10:33                      De-risking biotech investments in uncertain times11:57                      How investors are minimizing risk in 202513:35                      Funding trends for biotechs in emerging hubs, including Benelux15:58                      The deal types that will dominate 202517:35                      The therapeutic areas where deals are being done19:16                      Trends in biotech in Europe, in North America, and in the Asia-Pacific20:36                      Macroeconomics and biotechnology finance22:54                      De-risking deals by lowering upfronts, increasing milestones26:38                      What to consider when choosing alternative financing options30:35                      When should biotechs bring in outside finance experts33:47                      Looking beyond 2025 – what's coming, and why36:38                      How European biotechs can position themselves for funding successInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 2025 biotech funding tracker: recent highlightsThe ABC of biotech startup fundingTop biotech grants and campaigns

Art Bell - Michael Fumento - Biotechnology Developments

In this episode we are exploring two publications related to cancer care. In our first segment we talk to 2 authors about their research on genetic counselors and identification of patients for high-risk pancreatic cancer screening. In our second segment, Khalida interviews a genetic counselor about their study to evaluate surgical patient perspectives of genetic testing provided by a non-genetics professional.  Segment 1: “Practices and perspectives of genetic counselors about high-risk pancreatic cancer screening: A cross-sectional survey study” Amy Wiegand is a board-certified genetic counselor who specializes in cancer genetics. She graduated with her Master's in Genetic Counseling in 2017 from from the Icahn School of Medicine at Mount Sinai and has worked as a cancer genetic counselor at the Smilow Cancer Genetics and Prevention Program at Yale-New Haven Health since 2017 where she has seen over 2500 patients for a variety of hereditary cancer indications. Her research interests include hereditary pancreatic cancer and alternative delivery care models for genetic testing. Aparna is a senior genetic counseling assistant (GCA) at Smilow Cancer Genetics and Prevention Program at Yale New Haven Health where she has worked since 2019, and she has over 6 years of experience as a GCA. She holds a Master's degree in Biomedical Genetics and a Bachelor's degree in Biotechnology. She also has a varied background in administration, finance and customer service. She is a high-performing individual and was recently recognized by her colleagues as ‘Employee of the Quarter' and honored by the organization as ‘Smilow Star' for consistently going above and beyond for the patients and the co-workers and for exemplifying the health system's values. She contributes to the program in a variety of other ways outside of her role and works collaboratively with the team to create a patient centered environment. She has a strong interest in Cancer Genetics and is passionate about research. She is currently working on another research project, the abstract of which was selected for presentation in a Poster Session at 2025 ASCO (American Society of Clinical Oncology) annual meeting. She enjoys being part of a collaborative and dynamic team at Smilow Cancer Genetics and Prevention program and is excited about the upcoming research initiatives in the program. In this segment we discuss: - The significance of pancreatic cancer surveillance for high-risk individuals and why early detection plays a critical role in improving outcomes. - How genetic counselors are uniquely positioned to identify and refer individuals at high risk for pancreatic cancer, emphasizing their role in screening efforts. - An overview of the 2019 CAPS (Cancer of the Pancreas Screening) consensus guidelines and how they are applied to identify high-risk individuals for surveillance - The finding that nearly 70% of genetic counselors accurately identified individuals eligible for screening and discussed the factors that may have contributed to this high rate. - The association between provider comfort level and accuracy in identifying high-risk individuals, and discussed strategies to improve provider confidence and access to screening programs.   Segment 2: “Patient experiences of cancer genetic testing by non-genetics providers in the surgical setting” Katie Fiallos is a board-certified genetic counselor who earned her Master of Science in Genetic Counseling from the Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training program in 2017 and worked for seven years as a cancer genetic counselor at Johns Hopkins. She joined the Department of Medical and Molecular Genetics at Indiana University in August 2024. She is fluent in Spanish and provides genetic counseling in English and Spanish to participants with Parkinson's disease enrolled in the PD GENEration study. She has authored several academic papers related to genetic counseling, and her current research interests include provision of genetic counseling to Latine individuals, alternate service delivery models, and patient experiences with genetic testing and their informational desires. She lives in Michigan with her family and enjoys staying active, particularly practicing aerial silks. The research for the paper we're discussing was done while she was at Johns Hopkins and was funded by the Jennifer L. Brager Memorial Research award through the Johns Hopkins Kimmel Cancer Center.   In this segment we discuss: - Why hereditary cancer genetic testing is becoming increasingly important for patients with breast cancer, especially in relation to surgical decision-making. - The findings that patients preferred genetic testing at an existing appointment shortly after diagnosis, and explored how this timing affects their overall experience. - How many patients had already considered or wanted genetic testing before it was offered, shedding light on patient awareness and readiness. - Why patients were primarily motivated by concern for relatives and a desire for complete information, rather than surgical decision-making. - Gaps in patient-provider communication identified in the study and suggested ways for providers to address these issues in clinical practice.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Cette chronique explore un rapport américain sur l'alliance tech-défense, entre ambitions géopolitiques et dérives potentielles.Une lecture critique indispensable, là où l'éthique est curieusement absente.Philo Tech, la chronique philosophie de Trench Tech animée par Emmanuel Goffi.  ***** À PROPOS DE TRENCH TECH *****LE talkshow « Esprits Critiques pour Tech Ethique »Écoutez-nous sur toutes les plateformes de podcast

Send us a textEpisode Summary: Dr. Andrew Chadeayne discusses the chemistry of psilocybin and other psychedelics, their potential therapeutic applications, and the challenges of commercializing them in a shifting biotech market. The conversation delves into the complexities of magic mushroom composition, debunking myths like "lemon tekking," and uncovers the booming, unregulated alternative products industry, including kratom and synthetic psilocybin analogs sold in vape shops.About the guest: Andrew Chadeayne, PhD is a chemist who also holds a law degree, specializing in patent law. He is the founder and CEO of CaaMTech, a startup specializing in the development of novel psychedelic compounds. Chadeayne collaborates with academic labs to advance psychedelic science while navigating the commercial landscape.Discussion Points:Psilocybin is a prodrug converted to psilocin, but magic mushrooms contain other psychoactive molecules like beta-carbolines, which may enhance effects by inhibiting degradation.Chadeayne's team develops psilocin prodrugs to shorten psychedelic trips, making clinical administration more manageable without altering effects.The "lemon tek" myth—that lemon juice converts psilocybin to psilocin—is false; it enhances absorption by extracting compounds, not altering chemistry.Magic mushroom bruising indicates psilocin degradation, as oxidized psilocin forms blue, inactive dimers.The multi-billion dollar alternative products industry sells kratom and synthetic psilocybin analogs, often mislabeled, in vape shops, raising safety and regulatory concerns.Kratom's minor alkaloid, 7-hydroxymitragynine, is ~40x more potent than morphine, with no reported overdoses but high habit-forming potential.Non-hallucinogenic serotonin 2A agonists, like those developed by CaaMTech's spinout, show promise for conditions like migraines without requiring a psychedelic trip.Related episode:M&M 71: Chemistry of Magic Mushrooms, DMT Analogues, Entourage Effects in Cannabis & Fungi, Novel Psychedelic Medicines, Psychedelic Startups | Andrew Chadeayne*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

Mariano Mattei is the Vice President of Cybersecurity and AI at Azzur Solutions, bringing over 30 years of expertise in cybersecurity, AI innovation, and software engineering. A Certified Chief Information Security Officer (CCISO), Mariano has led AI-driven transformations across Biotechnology, Pharmaceuticals, and Medical Device sectors, integrating AI into clinical trials, manufacturing automation, quality systems, and regulatory compliance frameworks (FDA 21 CFR Part 11, GAMP 5, GDPR, HIPAA). His work spans predictive analytics for risk management, AI-powered process optimization, anomaly detection in manufacturing, and regulatory AI governance. He recently graduated from Temple University's Master's Program in Cyber Defense and Information Assurance, and he's the author of "Data-Driven Cybersecurity – Proven Metrics for Reducing Cyber Risk"Listen NOW to discover, "The Secret to Taking A Secure Risk"

The May All In For Citrus podcast features highlights from a recent OJ Break hosted by the University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) Citrus Research and Education Center (CREC) in Lake Alfred. Podcast host Frank Giles caught up with Michael Rogers, CREC director, during the event. Rogers summarized some of the information presented at the OJ Break, including a talk by Nian Wang, UF/IFAS professor and Graves Eminent Scholar Endowed Chair in Biotechnology, on his work to develop a CRISPR citrus tree with resistance to HLB. Wang has already engaged with the regulatory agencies required to get a CRISPR tree approved for commercial use by growers. Those agencies include the U.S. Department of Agriculture and Florida Department of Agriculture and Consumer Services. Rogers said the good news is a CRISPR tree is not a transgenic genetically modified plant, which means the regulatory process is easier to navigate. When a tree is proven to work in real-world grove conditions, it can be moved to growers more quickly. But Rogers added it will take time to identify the right tree. In addition, Wang discussed an observation he made during his research on letting some rootstock shoots grow up into the canopy of the tree. Some rootstocks have proven to be more tolerant to HLB. “Studies have shown that the root-die off from HLB is caused by carbohydrate starvation, because the plant is not moving the carbohydrates down to roots from the leaves,” Rogers explained. Wang observed that the rootstock shoots act as a means to move carbohydrates down to the roots. This could help sustain roots in HLB-infected trees. “I want to be clear this an observation and not a recommendation from UF/FAS,” Rogers said. “But it might spark some ideas with growers as it did today with the OJ Break audience. And that's a fact that some of our rootstocks are very tolerant to HLB on their own.” Also discussed in the May episode of All In For Citrus is managing the growing problem with snails in citrus as well as survey results on grower attitudes toward trunk injection of oxytetracycline. The podcast is a partnership between UF/IFAS and AgNet Media.

This lecture is entitled Quandaries of Biotechnology: Theory and Practice - Session 1. It was presented by Kyle Karches of Saint Louis University and Stephen Meredith of the University of Chicago on March 22, 2024, at the University of Chicago.

This lecture is entitled Quandaries of Biotechnology: Theory and Practice - Session 2. It was presented by Lesley Rice of the Pontifical John Paul II Institute and Silvianne Aspray of Cambridge University on March 22, 2024, at the University of Chicago.

Die Themen in den Wissensnachrichten: +++ Emanzipation zeigt sich auch an Barbie-Füßen +++ Meteorologen prognostizieren Hitzesommer für Europa +++ Nordseebakterium baut mit Bio-Spüli Ölteppiche ab +++**********Weiterführende Quellen zu dieser Folge:Flat out Fabulous: How Barbie's foot posture and occupations have changed over the decades, and the lessons we can learn/ Plos One, 14.05.2025.Anomalously Warm European Summers Predicted More Accurately by Considering Sub-Decadal North Atlantic Ocean Heat Accumulation/ Geopphysical Research Letters, 05.05.2025Biosurfactant biosynthesis by Alcanivorax borkumensis and its role in oil biodegradation/ Nature Chemical Biology, 09.05.2025Bedarfe von Kindern und Jugendlichen für ein gelingendes Aufwachsen/ Bertelsmann Stiftung, 15.05.2025Biomimetic chemical microhabitats enhance coral settlement/ Trends in Biotechnology, 14.05.2025.Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

The University of Virginia's Manning Institute for Biotechnology is set to be a “catalyst” for innovation in Virginia and beyond when it opens in 2026. 

EASY LISTENING DEP'T.: This is only about “dueling perspectives” in the same sense that New York City and Al-Qaeda had different ideas about the best use for the World Trade Center. Please visit, read, and support INDIGNITY! https://www.indignity.net/

On tonight's show, we will be discussing the newly formed partnership between Kids to Love & iXpressGenes! To share about this partnership, I'll have Kids to Love founder Lee Marshall & iXpressGenes CEO John Schmitt. As part of their trauma therapy program, a new test developed by iXpressGenes, an associate company at HudsonAlpha Institute for Biotechnology, will enable Kids to Love to tailor a client's therapy in order to get them the most effective treatment – combining cutting-edge science and compassionate care to help them heal.

In this episode, we sit down with the co-founder and CEO of Renew Biotechnologies to explore the groundbreaking work his company is doing in the field of early detection for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. Discover how a passion for research at BYU led to the creation of a company that's on the verge of changing the world. 00:00 - Introduction and guest welcome00:19 - From med school to biotech: The origin story00:51 - Early research and the birth of Renew Biotechnologies01:33 - Discussing Neuralink and the potential to cure ALS02:33 - How early detection can lead to cures02:44 - Introduction to Renew Biotechnologies and their focus03:54 - Success stories and the impact of their technology06:59 - The timeline and process for bringing a biotech product to market09:07 - The role of AI in diagnostics and healthcare10:28 - Long-term impact of AI in healthcare12:07 - Changes in administration and their impact on biotech14:21 - A day in the life of a biotech CEO15:57 - Company growth and future plans17:21 - Building a biotech company in Utah19:34 - Utah's biotech community and its growth21:53 - The role of universities in biotech innovation24:04 - Venture capital and funding challenges in biotech25:44 - Reading recommendations for CEOs26:30 - Balancing work with personal interests28:39 - Future vision for Renew Biotechnologies29:33 - Unique company structure and incentivizing innovation31:40 - The importance of integrity in healthcare33:10 - Acknowledging those who gave a chance If you enjoyed this video and want to support us please leave a LIKE, write a comment on this video and Share it with your friends. Subscribe to our channel on YouTube and click the icon for notifications when we add a new video. Let us know in the comments if you have any questions.  Our website: https://www.siliconslopes.comShow Links: https://www.renewbt.com Social:Twitter -https://twitter.com/siliconslopesInstagram -https://www.instagram.com/siliconslopes/LinkedIn -https://www.linkedin.com/company/silicon-slopes/YouTube -https://www.youtube.com/channel/UC8aEtQ1KJrWhJ3C2JnzXysw

Send us a textJoin Professor Jeffrey Sachs and futurist Ray Kurzweil for a compelling conversation on the accelerating pace of technological change and its profound implications for the future of humanity. In his new book, The Singularity Is Nearer, Kurzweil revisits and updates his groundbreaking predictions on AI & AGI, exponential growth, and human evolution and longevity.Together, they explore a future where AI rivals human intelligence by 2029, nanotechnology rebuilds the world atom by atom, and our minds merge with the cloud to expand intelligence beyond biological limits. They examine radical life extension, the promise of renewable energy, and how exponential technologies are reshaping industries, reducing poverty, and transforming global well-being. But, they also confront the risks while discussing a vision of the future - both awe-inspiring and cautionary - challenging us to rethink what it means to be human in an age of rapid and relentless innovation.The Book Club with Jeffrey Sachs is brought to you by the SDG Academy, the flagship education initiative of the UN Sustainable Development Solutions Network. Learn more and get involved at bookclubwithjeffreysachs.org.Footnotes:AIAGI The Singularity is Near Dartmouth WorkshopMartin Kosinski NeuromedBiotechnologyFrank RosenblattPerceptronExponential Growth Turing TestLongevity Humanoid RobotsVirtual Reality NeocortexArtificial Consciousness⭐️ Thank you for listening!➡️ Sign up for the newsletter: https://bit.ly/subscribeBCJS➡️ Website: bookclubwithjeffreysachs.org

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

The 3rd Annual Global Astrobiotechnology Hub focuses on advancing the intersection of space exploration, biotechnology, and innovation. The program brings together scientists, researchers, and space professionals to discuss how space technologies can accelerate scientific breakthroughs, particularly in fields like personalized medicine and bioengineering. Key themes include the challenges of conducting real-time research in space, the need for specialized astronaut-scientists, and the potential of space for groundbreaking experiments, such as organoid growth and in-space manufacturing. Experts underscore the importance of public access to scientific data and highlight the role of new media in engaging the public with space research. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40389]

https://youtu.be/oMFbMFvDJ50 Podcast audio: In this talk, Dr. Amesh Adalja details innovative new developments in science that will enhance the lives of individuals. Topics include transplantation of pig hearts and kidneys into humans, cell-based therapies for cancer, genetically modified mosquitoes, new vaccines and vaccine technologies, AI-discovered antibiotics, CRISPR therapeutics, and more. Recorded live on June 15 in Anaheim, CA as part of OCON 2024.

In this special episode of The Crop Science Podcast Show, we're marking International Seed Day, which is celebrated this month. Dr. Anuj Chiluwal from Kentucky State University joins us to talk about the connection between soybean yield and seed quality. He explains why seed protein levels are falling, what that means for growers, and how late-season nitrogen strategies and sustainable practices can help. Tune in now on all major platforms!"Nitrogen limitation during seed fill is the key reason for declining soybean protein levels."Meet the guest: Dr. Anuj Chiluwal earned his B.Sc. in Agriculture from Tribhuvan University, M.Sc. in Biotechnology from Fort Valley State University, and Ph.D. in Agronomy from Kansas State University. Currently, he is an Assistant Professor of Agronomy at Kentucky State University, focusing on soybean seed quality, nitrogen management, and crop physiology.Liked this one? Don't stop now — Here's what we think you'll love!What you will learn:(00:00) Highlight(01:02) Introduction(06:26) Soybean protein concentration(10:42) Yield vs. quality(14:17) Recommendations for growers(24:27) Fertilizer vs. fixation(29:02) Cultural practices(31:28) Final three questionsThe Crop Science Podcast Show is trusted and supported by the innovative companies:- CNH Reman- S&W Seed Co.- KWS

How does crowdfunding fit into a startup's fundraising strategy? In this intriguing episode of The Angel Next Door Podcast, host Marcia Dawood converses with guest Woodie Neiss about how crowdfunding has emerged as a transformative option for entrepreneurs seeking capital. The conversation unveils the ways securities-based crowdfunding is reshaping how new ventures are funded, making investments more accessible to various investors.Woodie Neiss, an experienced entrepreneur and a key advocate for crowdfunding legislation, shares his journey from Wall Street to becoming a pivotal figure in changing securities laws. His efforts have helped launch a thriving crowdfunding industry that offers over $2.8 billion in raised capital to more than 8,000 startups. He is also one of the founders of Crowdfund Capital Advisors (CCA), a crowdfunding advisory, implementation, and education firm.This episode is a must-listen for anyone involved in entrepreneurship, providing insights into significant crowdfunding developments and statistics. Woodie discusses how the industry has evolved, highlighting trends in sectors like healthcare and technology, and explaining how crowdfunding complements traditional fundraising strategies. Whether you're an investor, entrepreneur, or policymaker, this episode offers valuable perspectives on the current and future state of investment crowdfunding. To get the latest from Woodie Neiss, you can follow him below!https://www.linkedin.com/in/sherwoodneiss/https://crowdfundcapitaladvisors.com/https://a.co/d/f9987We - Investomers: How Customers-Turned-Investors are Shaping the Future of Early-Stage Finance Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

The Textile Innovation Podcast speaks with Jordan Schindler, CEO and founder of Clothing 2.0.Biotechnology company Clothing 2.0, in Conover, North Carolina, US, has developed a patented technology that infuses consistent doses of medicines, vitamins and supplements into yarn that create laundry-safe, reusable healing garments and textile products. We discuss how this category of products gives consumers better control of their health and wellness just by getting dressed. Schindler explains how Clothing 2.0 has developed numerous active ingredient infused products, from anti-fungal to eczema and acne treatments, with significant other applications currently under collaboration with industry leading partners.  Within this episode Schindler explores the company's recent collaboration with The Marena Group, a provider of medical-grade post-surgical compression garments, to assist patients undergoing invasive and minimally invasive aesthetic and plastic surgery procedures. He also touches upon the potential development of these garments with smart textile technology in the future. To learn more please visit clothing2.com.You can listen to the episode above, or via Spotify and Apple Podcasts. To discuss any of our topics, get in touch by following @wtincomment and @abi_wtin on X, formerly Twitter, or email aturner@wtin.com directly. To explore sponsorship opportunities, please email sales@wtin.com.

On this episode of the Defense & Aerospace Report Strategy Series, sponsored by General Atomics Aeronautical Systems, Dr. Dov Zakheim of the Center for Strategic and International Studies and a commissioner on the bi-partisan, bi-cameral National Security Commission on Emerging Biotechnology joins Defense & Aerospace Report Editor Vago Muradian to discuss the commission's final report released last week, “Charting the Future of Biotechnology.”

The I Love CVille Show headlines: How Would You Fix The UVA Health System? UVA Manning Institute Of Biotechnology Details UVA Biotech: $350M Facility, 350K SQ, 2026 Open 606 Delevan St: $300K Ask, 2BR, 1BA, 864SQ, 1960 Delevan St Listing Tear Down For 1/7th Of An Acre New Hill's Beacon Kitchen Open As Incubator What's Next Biz Incubator That Should Be Created? Kyle Guy Hired By University Of Nevada As Coach Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

In this week's episode, both of our storytellers share tales of persistence and beating the odds in order to pursue their scientific dreams. Part 1: Determined to become an academic, Rajyashree Sen must take on a broken system to secure a spot in a PhD program in Vienna. Part 2: Josh Barber dreams of studying fish, but when his father goes to jail and his mother is diagnosed with breast cancer, he's left to care for his nine younger siblings. Rajyashree Sen is a neuroscientist and postdoctoral researcher at Columbia University. She holds a PhD in neuroscience and molecular biology from the University of Vienna (Austria), and a masters degree in Biotechnology from the University of Hyderabad (India). As a graduate student with Dr. Barry Dickson, Dr. Sen dissected the neuronal pathways for evasive walking in fruit-flies. Her research focused on a set of neurons, dubbed the moonwalker neurons, that constitute the key pathway for backward walking in flies. Her work has been tweeted by MC Hammer. Dr. Sen is currently a postdoctoral fellow in the laboratory of Nobel Laureate Dr. Richard Axel, where she investigates the neuronal basis of social memories in mice. When she is not in the lab, she does improv comedy. While science has taken her to interesting places in interesting brains, improv has taken her to the moon, hell, back and beyond.  Josh is the Assistant Director of Aquatic Life at Columbia University where he oversees the well-being of various aquatic species in biomedical research. He's cohost of the Podcast "Gettin' Fishy With it" a podcast about fish in the wild, the hobby and the laboratory. His hobbies include improv comedy, ruining conversation flow with terrible puns, fishing, and fishing in his favorite videogame, World of Warcraft. Learn more about your ad choices. Visit megaphone.fm/adchoices

Caitlin Frazer, Executive Director of the National Security Commission on Emerging Biotechnology, joins Jeanne Meserve to discuss the intersection of biotechnology and national security. The conversation focuses on the growing strategic competition with China, and their new report “Charting the Future of Biotechnology.”For more information on the report, visit: https://www.biotech.senate.gov/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit scsp222.substack.com

Ep477-Art Bell-Michael Fumento-Biotechnology Developments